Robotics
PrivateA genuine #2 in soft-tissue surgical robotics with the only credible modular challenger to da Vinci — but revenue went BACKWARDS in FY2024 (£52.9M → £38.1M), the valuation has been frozen at $3B since 2021 across two insider-only rescue rounds, and the live ~$4B sale process is the tell: this is a tired venture asset shopping for a strategic exit, not a pre-IPO compounder. Watch the sale, not the story.
Research
The verdict
A genuine #2 in soft-tissue surgical robotics with the only credible modular challenger to da Vinci — but revenue went BACKWARDS in FY2024 (£52.9M → £38.1M), the valuation has been frozen at $3B since 2021 across two insider-only rescue rounds, and the live ~$4B sale process is the tell: this is a tired venture asset shopping for a strategic exit, not a pre-IPO compounder. Watch the sale, not the story.
CMR Surgical builds and sells one product: Versius, a robot-assisted surgical system for minimal-access soft-tissue surgery (general, gynaecology, colorectal, thoracic, urology). Strip the marketing and it is a capital-equipment-plus-consumables medtech in the same structural mold as Intuitive Surgical — sell a robot, then sell the single-use instruments and the service contract that ride on it for the life of the system — but a generation behind the incumbent in scale and a fraction of its size.
What actually differentiates Versius is architecture, not outcomes. Where da Vinci is a single large "boom" cart that dominates an OR, Versius is modular: each robotic arm is a separate, mobile, ~bedside-trolley unit that can be wheeled in, deployed in different configurations, and shared between operating rooms. The pitch is portability, a smaller footprint, better surgeon ergonomics (an open console, not a closed immersive hood), and a lower capital + per-procedure cost — explicitly aimed at cost-sensitive hospitals and markets that cannot justify a ~$2M da Vinci.
The plain-terms model — three revenue legs:
CMR also offers an "as-a-service" / Managed Service Provider (MSP) model that converts the heavy CAPEX purchase into a subscription or per-procedure fee — the standard tactic for a challenger trying to lower the adoption barrier against an entrenched leader. Direct sales were ~60% of revenue as of 2025; the rest goes through distributors/partners in markets like India and the Middle East.
Scale today (lifetime, cumulative — not annual):
Key regulatory unlocks: CE mark 2019 (Europe); FDA De Novo marketing authorisation October 2024 (first-gen Versius, cholecystectomy / gallbladder removal in adults — the gateway into the world's largest market); Versius Plus (second-gen) 510(k) clearance December 2025 for cholecystectomy (FDA letter K252111, 16-Dec-2025); a 510(k) for gynaecology filed April 2026 (benign hysterectomy, oophorectomy, salpingectomy). US commercialisation begins 2026.
Verdict on the model: a real, clinically validated, architecturally differentiated soft-tissue robot with a legitimate recurring-revenue flywheel — but the flywheel is tiny and, critically, not yet spinning the right way (FY2024 revenue fell; see Lens 5). The whole investment case rests on the US ramp finally converting the architecture advantage into installed-base growth, against the strongest moat in medtech.
Map Versius from inputs → CMR → end customer, naming the actual stakeholders:
Upstream (inputs / suppliers) →
The company (CMR) →
Downstream (channel → end customer) →
Chokepoints / single-source risk: (1) articulated instruments — few qualified suppliers, and this is the margin engine; (2) console via Tharsus — concentration on one manufacturing partner; (3) the US distribution build-out from scratch — CMR has no US installed base, no US service density, and must build a salesforce against Intuitive's entrenched account relationships. Supply is not CMR's problem; demand creation in the US is.
Be blunt: CMR is the challenger, and the moat in this industry belongs to the incumbent. The honest assessment is that CMR's "moat" is thin and its competitor's is among the widest in all of medtech.
What CMR genuinely has (modest, real):
What Intuitive has (and CMR cannot easily replicate):
Bargaining-power verdict: CMR is squeezed on both sides — strategic instrument suppliers it must "upskill," and customers who hold the option to buy the incumbent. The moat is the modular niche + cost + #2 status, which is defensible against #3 (Medtronic Hugo) but not a wedge wide enough to take share from da Vinci in da Vinci's core accounts. The bet is segment expansion (new hospitals/ASCs that buy a robot), not conversion.
CMR is private and does not publish audited segment revenue by product or geography. The seeded segments.csv is empty; there is no `` segment data. What can be assembled from web + UK statutory disclosure:
| Dimension | Read | Provenance |
|---|---|---|
| By product | Single product line (Versius / Versius Plus). Revenue split across (a) system placements, (b) recurring instruments/consumables, (c) service. The recurring mix is rising by design (Versius Connect, MSP), but exact split not disclosed. | n/a — not disclosed |
| By channel | ~60% direct, ~40% distributor/partner (2025) | |
| By geography | Core: UK + Europe + Australia; growth: India, Middle East, AMEA, LatAm; new: US (from 2026). North America = ~46% of the global market but ~0% of CMR's revenue today — the entire bull case is closing that gap. | |
| Trend | Decelerating / contracting at group level — total revenue £52.85M FY2023 → £38.1M FY2024, ≈ −28%. A commercial-stage robotics company whose revenue went backwards is the single most important segment fact in this dossier. |
Why the decline (best read): CMR scrapped its first US launch and delayed ~a year to re-engineer Versius Plus; combined with the 2023 restructuring (Lens 9) and a deliberate "rebalancing … for the markets in which it was selling," FY2024 looks like a strategic air-pocket year — system sales paused ahead of the next-gen platform and the US entry. Bulls call it a reset; bears call it a company that couldn't grow into its $3B valuation and had to retrench. Both are true. Either way: segment data is too thin to underwrite, and the only trend we can see is the wrong direction.
CMR has no earnings print. The equivalent "performance tape" for a private is the financing history — and CMR's tells a clear story: a hot 2019–2021, then a frozen valuation across two insider-led rescue-ish rounds, now an exit search.
| Round | Date | Amount | Lead / notable | Post-money valuation | Read | Provenance |
|---|---|---|---|---|---|---|
| Series A | 2016 | ~$20.3M | ABB Tech Ventures, LGT, Cambridge Innovation Capital | — | first institutional | |
| Series B/C era | through 2019 | (Series C ~$240M) | — | unicorn (≥$1B) at Series C 2019 | hype build | |
| Series D | Jun-2021 | $600M | SoftBank Vision Fund 2 (co-lead Ally Bridge Group; Escala largest holder) | $3.0B | peak — largest-ever European robotics raise | |
| Insider round | Sep-2023 | $165M (£133M) | existing investors only (SoftBank, Tencent, Ally Bridge, CIC, Escala, LGT, Lightrock, Railpen, Watrium) | flat — still ~$3B | bridge; no markup; no new lead | |
| Debt + equity | Apr-2025 | >$200M / >£154M (mix of equity + debt from Trinity Capital) | not re-struck (existing major investors) | structured / debt-heavy — venture-debt signals equity-financing fatigue |
Total raised: ~$1.32–1.35B over ~8–12 rounds.
What the trajectory says (the performance verdict):
Burn / balance sheet (UK statutory, FY2024): retained earnings ≈ −£123.2M (cumulative deficit); net assets +£144M (up from £68.8M, reflecting the fresh capital injected). Cumulative losses against a single-product, sub-£40M-revenue base — this is still a cash-consumptive, pre-profit company. Specific FY2024 pre-tax loss and cash runway figures are not surfaced in public web sources (would require pulling the filed accounts from Companies House directly) — n/a for the precise loss line.
No earnings calls exist. Substitute: the management narrative arc via interviews and announcements, and how the tone has shifted.
Sentiment shift: from moon-shot (2021) → survival/discipline (2023) → pragmatic-relaunch (2024) → execute-or-sell (2025–26). The throughline is a company that raised at the top, missed the growth it was priced for, cut hard, brought in a commercial operator (not a visionary founder) to run it, and is now positioning for a strategic exit. That is a turnaround/sale narrative, not a hyper-growth one. The recurring phrase is "expansion" and "access"; the phrase they stopped saying is anything implying an independent path to category leadership.
Cap table / syndicate quality. The register is broad and venture-heavy: SoftBank Vision Fund 2 (largest cheque, Series D lead), Escala Capital (largest holder per Wikipedia), Ally Bridge Group, Tencent, Cambridge Innovation Capital, LGT Capital Partners, Lightrock, RPMI Railpen, Watrium, ABB Technology Ventures; Trinity Capital now holds venture debt. Read on quality:
n/a. The relevant mark is the $3B primary (2021, stale) vs the ~$4B sale ask (2025) — and an ask is not a clearing price.Public comps (the listed surgical-robotics universe — what a strategic acquirer is benchmarked against):
| Company | Ticker | Mkt cap (USD) | EV/Sales | P/E (ttm) | Note | Provenance |
|---|---|---|---|---|---|---|
| Intuitive Surgical | ISRG | ~$172.6B | ~18x (P/S) | ~59x (fwd ~46x) | the moat; 70%+ I&A GM; rev +21% Q1'26 | |
| Medtronic | MDT | (rev ~$36.4B) | ~4.3x EV/rev | ~22x (fwd ~14x) | diversified; Hugo is one small line | |
| Stryker | SYK | ~$129.9B | ~5x (est) EV/EBITDA ~20x | ~21x | Mako (ortho) leader, not soft-tissue | |
| Johnson & Johnson MedTech | JNJ | — | — | — | owns Auris/Monarch + Ottava (delayed); $3.4B Auris deal | |
| PROCEPT BioRobotics | PRCT | (small-cap) | high-multiple growth | n/m (unprofit.) | closest "single-product growth robotics" analogue |
The valuation question for CMR specifically. CMR is being shopped at ~$4B on £38M ($48M) of declining revenue — an implied EV/Sales of roughly 80x. That is not a financial-buyer multiple and not supportable on fundamentals — it is a strategic / scarcity multiple: the price an acquirer pays for the only credible modular soft-tissue robot platform, CE+FDA cleared, with an instrument annuity and a US runway, to deny it to a rival and to bolt onto an existing hospital salesforce. Pure-financial comps (ISRG ~18x P/S on growing revenue; MDT ~4x EV/rev) say a rational standalone value is a fraction of $4B. The $4B is an option premium on strategic control, not a multiple on cash flows. Anyone underwriting CMR at the ask is underwriting an M&A outcome, not a business.
For a private, "what moves the stock" = the events that re-rate the private mark or change exit probability. Pattern over the last ~5 years:
What the pattern reveals: the story reacts to (1) regulatory unlocks (US clearances = upside), (2) financing structure (insider/debt rounds = the market saying "no markup"), and (3) the sale process (the dominant variable). The next real catalyst is a sale announcement — its presence, price, and identity of buyer — far more than any single quarter of US placements.
n/a — not disclosed. The governance reality: the financial sponsors, not the founders, are driving — and they want liquidity.Archetype verdict: professionalised, sponsor-controlled, sale-oriented. Competent operators stewarding a venture asset toward a strategic buyer. Bet on Colella to run a clean US launch and a clean sale — not to build an independent category champion.
No SEC exposure — CMR has no CIK; the pre-fetched regulatory/regulatory-findings.md confirms 0 SEC Litigation Releases / 0 AAERs (private, not an SEC filer). UK statutory accounts are filed at Companies House (08863657) but are abbreviated and unaudited to the depth of a public filing — so the usual forensic battery (revenue-recognition footnotes, segment reporting, SBC reconciliation, receivables vs revenue) cannot be run on primary documents. Label all of this `` / unaudited per public sources.
What can be assessed:
n/a — not disclosed.n/a — would require the filed accounts).Regulatory findings (required sub-section):
not independently verified against MAUDE/MHRA databases.The relevant forward question for a +private name is not an EPS model — it is how does this become liquid, at what value, and when. For CMR the honest answer is: the most probable liquidity event is a trade sale, not an IPO, and it may be imminent.
Three paths, with my probability read:
Trade sale to a strategic — BASE CASE (~55–65% over 12–24 months). The FT-reported ~$4B/£3.1B process is live and advisers are engaged. Logical acquirers: Medtronic (Hugo + Versius would consolidate the #2/#3 challenger position vs Intuitive — though overlap raises antitrust questions), J&J MedTech (Ottava is delayed and troubled; buying CMR could leapfrog it — but J&J was burned by the $3.4B Auris deal, now carrying a $1B+ earnout-fraud judgment, so it may be gun-shy), Stryker (soft-tissue would diversify it beyond Mako/ortho), or a larger player wanting instant soft-tissue scale. Clearing price is the open question — a strategic might pay a scarcity premium toward $3–4B, or the declining revenue + flat-mark history could drag the print below the last $3B round (a structurally disappointing exit for late money).
IPO — LOW (~10–15%). An IPO needs growth and a fresh narrative to price; CMR has a flat mark, a declining-then-resetting top line, and no crossover investors pre-positioning it. A US listing only becomes plausible after a successful, visibly accelerating US ramp (2026–27+). The signal that would raise this probability — a Fidelity/T. Rowe/Coatue markup round — has conspicuously not happened.
Another private round / status quo — MODERATE (~25–30%). If the sale process clears below expectations or stalls, CMR raises again (more insider + debt) and keeps executing the US launch. This is the "muddle through" path; it preserves optionality but continues the dilution/debt creep and the frozen mark.
Milestones that unlock a tradeable outcome (what to watch):
Brier forecast (the binary that matters for a private): Rather than an EPS line, the trackable call is on the liquidity event:
"CMR Surgical announces a definitive sale (change of control) by 2026-12-31." — base probability ~0.40. (A process is live, but M&A processes frequently slip, re-price, or fail; antitrust overlap with the most-logical buyer, Medtronic, adds friction.) No
forecast.ts createis logged in the watchlist loop per skill rules — recorded here for the analyst to log if promoting to a view.
The number for a buyer's model: at the ~$4B ask on ~$48M revenue (~83× sales), the deal only pencils if an acquirer believes Versius can reach $400–600M+ of revenue at maturity (a ~7–10× sales exit on that base) by riding the US ramp + instrument annuity to a meaningful slice of a ~$16.4B-by-2030 surgical-robotics market. That requires CMR to do in the US what it failed to do at the valuation it was given in 2021. Plausible for a strategic with distribution; not underwritable as a standalone.
Bull case. CMR is the only credible, independent, modular soft-tissue robot in the world that is CE and FDA cleared — a genuinely scarce strategic asset. The architecture (portable, multi-arm, smaller footprint, lower cost, open console) addresses a real underserved segment Intuitive's monolithic da Vinci can't serve well: smaller hospitals, ambulatory surgery centres, and price-sensitive geographies. With ~45,000 procedures, 128 procedure types, a dedicated 500-system/yr factory, and a razor-blade instrument annuity beginning to compound (Versius Connect/MSP), the platform is real and de-risked. The Oct-2024 De Novo + Dec-2025 Versius Plus 510(k) + 2026 gynaecology filing open the world's largest market just as a commercially seasoned ex-J&J CEO takes over. In a ~$9–11B → ~$16–21B-by-2030 market growing low-teens, even modest US share-capture inflects revenue hard. And the kicker: a live ~$4B strategic sale to Medtronic / J&J / Stryker offers a near-term liquidity event at a scarcity premium — you may not need to wait years for the ramp.
Bear case (the things that permanently impair).
Pre-mortem (18 months out, thesis broke — what happened?): The US launch under-delivered (Versius Plus placements trickled in against entrenched da Vinci accounts and a well-funded Hugo); the sale process failed to clear $3B (buyers used the declining revenue and Auris-scar caution to lowball, antitrust spooked Medtronic); CMR raised another insider+debt round at a flat-or-lower mark; SoftBank wrote the position down again. The platform was real, but being the better #2 was never enough to escape Intuitive's gravity or to justify the 2021 mark.
Are multiples too high? On any fundamental basis, yes — emphatically. The ~$4B ask is justifiable only as M&A scarcity value. As a standalone, a financial buyer's number is a fraction of that.
Contrarian view (what the market refuses to see): The consensus frame is "exciting #2 challenger with a US catalyst." The contrarian read is that CMR is a tired, sponsor-controlled venture asset whose own cap table is trying to sell it — and that the most likely "catalyst" is a sale that disappoints the headline $4B, because the only buyer who'd pay full scarcity price (Medtronic) faces antitrust overlap, and the one who needs it most (J&J) is scarred by Auris. The asymmetry skews to a down-exit, not an up-one.
Dismantling the bull case — if this were shortable:
A best-in-class MedTech compounder whose 8-9.5% organic engine is intact, but at ~20x forward EPS the stock already prices the cyber-attack recovery as a formality — the bet is that a $375M Q1 air-pocket is timing, not a dent in the franchise.
A genuine top-3 global robotaxi platform finally crossing city-level unit-economics breakeven — but priced for execution it has not yet earned, with a related-party-and-China-permit overhang that the −65% drawdown is screaming about; net-cash floor + founder 540-day lockup make it a WATCHING name to size on proof of fleet-scaling through the permit freeze, not a chase here.
A spine-implant roll-up wearing a robotics badge — the robot is <5% of revenue and a razor-and-blade pull-through, not the story; the real bet is whether mid-single-digit organic growth re-accelerates as NuVasive integration scars heal, at a justified ~16x value-medtech multiple.